Shares of Exelixis, Inc. EXEL have surged 50% in a year against the industry’s decline of 16.1%. The stock has also ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III drugs for Oropharyngeal Cancer have a 17% phase ...

Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...

Another promising candidate in Exelixis’ pipeline is zanzalintinib, a next-generation oral. Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $42 from $33 and keeps a Buy rating on the shares.

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

The focus now turns to Exelixis's drug zanzalintinib, a multi-kinase inhibitor currently undergoing trials for colorectal cancer (CRC). While the probability of success for zanzalintinib in CRC ...

Enrollment has been completed in the late-stage STELLAR-303 study evaluating zanzalintinib, in combination with Tecentriq, compared with regorafenib in patients with metastatic refractory ...

Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.